KR101628962B1 - manufacturing method of preventing and ameliorating constipation thereof - Google Patents
manufacturing method of preventing and ameliorating constipation thereof Download PDFInfo
- Publication number
- KR101628962B1 KR101628962B1 KR1020140046804A KR20140046804A KR101628962B1 KR 101628962 B1 KR101628962 B1 KR 101628962B1 KR 1020140046804 A KR1020140046804 A KR 1020140046804A KR 20140046804 A KR20140046804 A KR 20140046804A KR 101628962 B1 KR101628962 B1 KR 101628962B1
- Authority
- KR
- South Korea
- Prior art keywords
- defibrillator
- lactic acid
- aqueous solution
- acid bacteria
- extract
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
Abstract
The present invention relates to an agent for preventing and improving constipation and a method for producing the same, which is capable of preventing and improving constipation by inoculating lactic acid bacteria and fermenting lactic acid bacteria into a luciferase powder or a luciferase extract, And supplying an antifoaming agent to prepare an aqueous solution of a defibrillator; (B) feeding the culture solution of lactic acid bacteria to the aqueous solution of the recipient; A step of sterilizing the aqueous solution of the defibrillator supplied with the lactic acid bacteria growth medium; (C) inoculating the aqueous solution of the defibrillator treated with the sterilized lactic acid bacteria; Fermenting an aqueous solution of a lysate of the lactic acid bacteria inoculated; ≪ - > centrifuging the fermented fermentation broth to obtain a supernatant liquid
Description
The present invention relates to a method for preventing and improving constipation and a method for producing the same, which can prevent and ameliorate constipation by inoculating and fermenting lactic acid bacteria to a Cucumber powder or a Cacterium extract.
Constipation is one of the most common symptoms observed in clinical practice. It is frequently experienced in 5-20% of the whole population, but it is difficult to define objectively because it is a symptom group with a wide variety of expressions.
More than 90% of patients with constipation are idiopathic chronic idiopathic constipation without a causative disease, and secondary constipation is secondary to constipation, such as intestinal intestinal lesions, metabolic diseases, and the use of certain medications.
Chronic constipation is reported to be associated with the risk of impairing quality of life and causing colon and rectal cancer. In the treatment of constipation, it is important that the dietary supplement is sufficient for the prevention and treatment of constipation. It is a plant ingredient that can not be digested by intestinal enzymes, Lighten the sides and increase the volume.
In addition, it helps to grow colon bacillus to increase the extent of damage, and some of the components are fermented by bacteria in the colon, the metabolism is also helpful for constipation relief. In addition, there are reports that people with a lot of physical activity have less constipation.
However, patients who do not have easy diet and exercise can use secondary drugs. In the case of volumetric emollients and osmolality modifiers, abdominal distension and diarrhea may be accompanied. In the case of stimulant laxatives, long-term use may cause various complications have.
These symptoms are usually treated by simple procedures or taking laxatives to see bowel movements without pain, but many constipation patients are not satisfied with this method and are interested in other therapies.
The present invention relates to a method of preventing or ameliorating constipation and a method of preventing and improving constipation by preparing a lactic acid bacterium growth culture by inoculating a lysimeter powder or a lysimeter extract into distilled water, The present invention has been made in view of the above problems.
According to a first aspect of the present invention, there is provided a method for preparing a defibrillator, comprising the steps of: (a) preparing a defibrillator aqueous solution by supplying a defibrillator powder and defoamer to distilled water; (B) feeding the culture solution of lactic acid bacteria to the aqueous solution of the recipient; A step of sterilizing the aqueous solution of the defibrillator supplied with the lactic acid bacteria growth medium; (C) inoculating the aqueous solution of the defibrillator treated with the sterilized lactic acid bacteria; Fermenting an aqueous solution of a lysate of the lactic acid bacteria inoculated; Centrifuging the fermented fermentation broth to obtain a supernatant; .
In order to achieve the above object, a second embodiment of the present invention is a method for extracting a catechol extract, comprising the steps of: (a) extracting an active ingredient of a cuttlefish to obtain a cuttlefish extract; (B) preparing an aqueous solution of a defibrillator by adding a defibrillator extract and defoamer to distilled water; Feeding lactic acid bacteria growth medium to the aqueous solution of the recipient; A step of sterilizing the aqueous solution of the defibrillator supplied with the lactic acid bacteria growth medium; ≪ tb >< tb >< / TABLE > (C) fermenting an aqueous solution of the recipient inoculated with the lactic acid bacteria; Centrifuging the fermented fermentation broth to obtain a supernatant; .
The supernatant obtained by the above method is effective for prevention and improvement of constipation by eliminating the heat of the liver and actively inducing peristalsis of the large intestine.
1 to 7B are graphs showing the results of experiments of the supernatant obtained by the present invention on animals (rats)
8A to 8F are graphs showing the results obtained by inoculating lactic acid bacteria and fermenting them by date according to the invention of the first embodiment,
9A to 9C are graphs showing the results obtained by inoculating lactic acid bacteria and fermenting them by date according to the invention of the second embodiment.
Hereinafter, examples of the composition for preventing and / or improving constipation of the present invention will be described.
Constipation Prevention and Improvement Agent of the Present Invention The manufacturing method of the first embodiment will be described in detail as follows.
(A) preparing an aqueous solution of a defibrillator by supplying a defibrillator powder and defoamer to distilled water; (B) feeding the culture solution of lactic acid bacteria to the aqueous solution of the recipient; A step of sterilizing the aqueous solution of the defibrillator supplied with the lactic acid bacteria growth medium; (C) inoculating the aqueous solution of the defibrillator treated with the sterilized lactic acid bacteria; Fermenting an aqueous solution of a lysate of the lactic acid bacteria inoculated; ≪ - > centrifuging the fermented fermentation broth to obtain a supernatant.
Step (a)
The step (a) of the present invention is a step of preparing an aqueous solution of a defibrillator by supplying a defibrillator powder and a defoaming agent to distilled water,
The Cassia tora, the beans and has mainly been widely cultivated in (Leguminosae) and mountain of the one year old herbal the climate is temperate South Korea fat belonging to, physiologically active functions, antimicrobial, insecticidal, mutation inhibiting, antiallergic, removing periodontal disease pathogens , Antioxidant, liver protection, blood pressure lowering, blood lipid lowering effect, blood glucose lowering and so on.
The main pharmacological components of the above-mentioned cleansers include chrysophanol, emodin, aloe-emodin, torachryson, rubrofusarin-6-gentiobioside, nor-rubrofusarin, aurantio-obtusin, rubrofusarin, toralactone, rhein, physcion, obtusifolin, obtusin and chryso- .
In particular, the emodin component of the cleanser has a mitigating effect, chrysophanic acid-90anthrone inhibits the development of dermatophytes, has a bactericidal action, and has been reported to exert gastric secretion when administered to fasting stomachs.
In the efficacy experiments, studies on platelet aggregation inhibition components and alcohol extracts extracted from the seedlings were reported to be excellent in preventing liver damage caused by carbon tetrachloride. Hypoglycemic effect and nitrite scavenging factors were reported.
The above-mentioned potatoes having the above-mentioned effect are used in the form of powder, which is dried after being washed, washed and ground by a pulverizer, and the amount of the powder of the Crysant powder in the powdered state is supplied so as to maintain the concentration of the Crysant powder at 2 to 8%.
The amount of the saccharide powder to be supplied so as to maintain the concentration of the saccharide powder of 2 - 8% may be supplied in a ratio of 20 - 80 g of the saccharide powder to 0.9 - 1.2 L of the distilled water.
The reason why the concentration of the crystallization powder should be maintained at 2 to 8% is that if the concentration of the crystallization solution is less than 2%, the crystallization concentration of the crystallization solution is too weak. If the crystallization concentration exceeds 8% Problems arise.
Therefore, it is desirable to maintain the concentration of the crystalloid powder in the aqueous solution of the crystalloid solution of 2 - 8%.
The antifoaming agent is used in order to prevent the generation of bubbles in the fermentation process described in the following step 것으로, and the amount of the antifoaming agent used is 30 to 70..
If the amount of the defoaming agent used is less than 30 μl, the foaming can not be prevented. If the amount of the defoaming agent is more than 70 μl, the amount of the defoaming agent is preferably 30 to 70 μl.
Examples of the antifoaming agent include decanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, One selected from the group consisting of mineral oil, oxystearine, dimethyl polysiloxane, silicon dioxide, sorbitan monostearate, and silicon resin is used.
Step b)
The step (b) of the present invention is a step of supplying a lactic acid bacterium growth medium to an aqueous solution of a defibrillator,
The lactic acid bacteria growth medium means the lactic acid bacterium food that the lactic acid bacteria can eat. The reason why the lactic acid bacteria growth medium is added to the defibrillator solution is that fermentation is effectively performed by inducing lactic acid bacteria growth in the fermentation process described in the following step .
The lactic acid bacteria growth medium in step (b) is Proteose Peptone, Beef Extract, Yeast Extract, Dextrose, Polysorbate 80g, Ammonium Citrate, Sodium Acetate, Magnesium Sulfate, Manganese Sulfate and Dipotassium Phosphate.
The amount of the lactic acid bacteria growth medium to be supplied to the aqueous solution of the lysimeter was 3 ± 1 g of Proteose Peptone, 3 ± 1 g of Beef Extract, 1.5 ± 1 g of Yeast Extract, 6 ± 1 g of Dextrose, 0.3 ± 0.2 g of Polysorbate 80 and 0.6 ± 0.2 g of Ammonium Citrate 0.6 ± 0.2g, Sodium Acetate 1.5 ± 0.3g, Magnesium Sulfate 0.03 ± 0.005g, Manganese Sulfate 0.015 ± 0.005g, Dipotassium Phosphate 0.6 ± 0.005g.
Step
The step of the present invention is a step of sterilizing the growth medium of the lactic acid bacteria. The reason for sterilizing the lactic acid bacteria growth medium is to sterilize the harmful bacteria in the aqueous solution of the defibrillator, - High pressure steam sterilization for 20 minutes.
The reason for setting the sterilization temperature at 115-125 DEG C is that sterilization is not effectively performed at a temperature lower than 115 DEG C, the productivity is deteriorated due to a longer sterilization time, and when the temperature exceeds 125 DEG C, It is preferable that the temperature of the sterilization is 115 to 125 ° C since the nutrients are destroyed with the sterilization.
Step
The step of the present invention is a step of inoculating a sterilized aqueous solution of a defibrillator into a solution of lactic acid bacteria,
The lactic acid bacteria may be selected from the group consisting of Lactobacillus kefiri , Lactobacillus kefiranofaciens , Lactobacillus acidophilus , Lactobacillus paracasei , Enterococcus faecium , Lactobacillus casei , Lactobacillus plantarum , Lactobacillus amylophilus , Lactobacillus fermentum , Lactobacillus curvatus , Lactobacillus bulgaricus , Lactobacillus delbrueckii , Bifidobacterium breve , Acetobacter lovaniensis , Acetobacter fabarum And Leuconostoc mesenteroides ≪ / RTI >
The lactic acid bacteria inoculation may be inoculated at a ratio of 0.9 to 1.2 L of the sterilized luciferase aqueous solution and 30 to 50 mL of the lactic acid bacterium.
The amount of the lactic acid bacteria inoculated is 30-50 ml because, if the amount is less than 30 ml, the amount of lactic acid bacteria inoculated is too small, and if it exceeds 50 ml, the amount is in excess. Therefore, the inoculation of lactic acid bacteria is preferably 0.9 to 1.2 liters of lactic acid bacteria growth medium and 30 to 50 ml of lactic acid bacteria.
Step
The step of the present invention is a step of fermenting an aqueous solution of a cleanser inoculated with lactic acid bacteria,
The fermentation method is performed by supplying oxygen at 35 to 40 ° C. and fermenting with stirring at 120 to 180 RPM. The reason for supplying the oxygen is to facilitate fermentation due to active growth of lactic acid bacteria, The reason is to prevent sediment from being generated when fermented.
When the temperature is lower than 35-40 ° C, the fermentation is not normally performed. If the stirring speed is lower than 120RPM, the precipitate is formed. If it exceeds 180 RPM, the fermentation is inhibited.
Therefore, it is preferable that the fermentation condition is stirred at a temperature of 35 - 40 캜 and 120 - 180 RPM.
The results of inoculating the lactic acid bacteria and fermenting them by date are shown in Figs. 8A to 8F.
Figure
FIG. 8B shows the
FIG. 8C shows that Lactobacillus paracasei 30 ml inoculated,
FIG. 8d shows the
Figure 8E shows that
Figure 8f shows that Enterococcus 50cm of faecium is inoculated.
Step
The step of the present invention comprises a step of centrifuging the fermented fermentation broth to obtain a supernatant,
The centrifugation conditions are 5,000 to 10,000 RPM for 10 to 20 minutes because the supernatant to be obtained in the present invention is completely separated from the precipitate to obtain only a supernatant of good quality.
If the centrifugation speed is less than 5,000 RPM, the productivity is deteriorated due to the delay of obtaining the supernatant alone, and the 10,000 RPM or more is more than necessary. Therefore, the centrifugation conditions are preferably 5,000 to 10,000 RPM.
The supernatant prepared and obtained as described above is used as a preventive and remedy for constipation of the present invention.
The method of manufacturing the constipation prevention and remedy of the second embodiment of the present invention will be described in detail as follows.
A second embodiment of the present invention is a method for preventing and /
(A) extracting the active ingredient of the defibrillator to obtain a defibrillator extract; (B) preparing an aqueous solution of a defibrillator by adding a defibrillator extract and defoamer to distilled water; Feeding lactic acid bacteria growth medium to the aqueous solution of the recipient; A step of sterilizing the aqueous solution of the defibrillator supplied with the lactic acid bacteria growth medium; ≪ tb >< tb >< / TABLE > (C) fermenting an aqueous solution of the recipient inoculated with the lactic acid bacteria; Centrifuging the fermented fermentation broth to obtain a supernatant; .
Step (a)
The step (a) of the second embodiment of the present invention is a step of extracting an active ingredient of a defibrillator to obtain a defibrillator extract, and the description of the defibrillator is the same as that of the first embodiment.
In the second embodiment of the present invention, the cutter used in the present invention is a cutter, which is dried after being washed, cleaned or washed, and then pulverized by a crusher to obtain a powder.
The extraction method for extracting the active ingredient of the above-mentioned cutter or the cutter powder comprises mixing the cutter-dried cutter or the cutter powder at a ratio of 1 wt% of distilled water to 9-11 wt% of distilled water to form a mixture; Heating the mixture to 100 - 120 캜 for 2 - 4 hours; Filtering the suspended matter or precipitate after cooling the heated Cassiae extract; Concentrating the filtered killer extract at reduced pressure; Lyophilizing the concentrated concentrate under reduced pressure; 45 to 55% by weight of the lyophilized cleanser, and 0.9 to 1.2 L of distilled water.
(B) step;
Step (b) of the second embodiment of the present invention is a step of preparing an aqueous solution of a defibrillator by adding a defibrillator extract and an antifoaming agent to distilled water, which is the same as the description of the step of preparing a defibrillator aqueous solution of the first embodiment described above, and a description thereof will be omitted.
However, when preparing the aqueous solution of the defibrillator in the step (b), 30-70 g of the defatant extract and 30-80 g of the Defatant extract are supplied to 0.9-1.2 liters of distilled water. The reason why the defatant extract is used is 30-80g, unlike the first embodiment, This is because the extracts extracted by the method are used.
Step
The step of the second embodiment of the present invention is a step of supplying a lactic acid bacteria growth medium to the aqueous solution of the defibrillator,
The lactic acid bacteria growth medium means feeding the lactic acid bacteria that the lactic acid bacteria can eat. The reason why the lactic acid bacteria growth medium is supplied to the defibrillator aqueous solution is that the lactic acid bacteria growth is actively induced in the fermentation process described in the following step .
The lactic acid bacteria growth medium in the above step is Proteose Peptide, Beef Extract, Yeast Extract, Dextrose, Polysorbate 80g, Ammonium Citrate, Sodium Acetate, Magnesium Sulfate, Manganese Sulfate and Dipotassium Phosphate.
The amount of the lactic acid bacteria growth medium to be fed to the aqueous solution of the lysimeter was 1.5 ± 0.5 g of Proteose Peptone, 1.5 ± 0.5 g of Beef Extract, 1 ± 0.5 g of Yeast Extract, 3 ± 1 g of Dextrose, 0.2 ± 0.1 g of Polysorbate 80, 0.3 ± 0.1 g of Ammonium Citrate, 1 ± 0.2 g of Sodium Acetate, 0.01 ± 0.003 g of Magnesium Sulfate, 0.01 ± 0.003 g of Manganese Sulfate and 0.3 ± 0.003 g of Dipotassium Phosphate.
Step
Step
The lactic acid bacteria may be selected from the group consisting of Lactobacillus kefiri , Lactobacillus kefiranofaciens , Lactobacillus acidophilus , Lactobacillus paracasei , Enterococcus faecium , Lactobacillus casei , Lactobacillus plantarum , Lactobacillus amylophilus , Lactobacillus fermentum , Lactobacillus curvatus , Lactobacillus bulgaricus , Lactobacillus delbrueckii , Bifidobacterium breve , Acetobacter lovaniensis , Acetobacter fabarum And Leuconostoc mesenteroides ≪ / RTI >
In the inoculation of the above-mentioned lactic acid bacteria, 30 to 50 ml of lactic acid bacteria may be inoculated in 0.9 to 1.2 liters of the sterilized aqueous solution of the defibrillator.
The amount of the lactic acid bacteria inoculated is 30-50 ml because, if the amount is less than 30 ml, the amount of lactic acid bacteria inoculated is too small, and if it exceeds 50 ml, the amount is in excess. Therefore, the inoculation of lactic acid bacteria is preferably 0.9 to 1.2 liters of lactic acid bacteria growth medium and 30 to 50 ml of lactic acid bacteria.
Step
The results obtained by inoculating the lactic acid bacteria of the present invention and fermenting them by date are shown in Figs. 9A to 9C.
9A is a
Figure 9b shows that Lactobacillus paracasei 50 ml inoculated,
Figure 9c Enterococcus 50cm of faecium is inoculated.
Step
The results obtained by experimenting the obtained product of the present invention, i.e., the supernatant, prepared in the same manner as the above-described method, on an animal are as follows.
1) Experimental animal breeding and empirical formula
Sprague-Dawley rats (SD) and 4-week-old males were purchased from Multiscience (Daejeon, Korea) and cultured at a temperature of 20 ± 2 ℃ and humidity of 55 ± 5% for 12 hours.
Experimental animals were purified for 1 week after purchase, and 5 animals were placed per group, and the experimental groups were classified into 7 groups.
(SA-2, 200 mg / kg), low-concentration (SA-1, 100 mg / kg) and low concentration (SC-1, 100 mg / kg) and high-concentration celery fermentation extract (SC-2, 200 mg / kg)
As a positive control, a constipation therapeutic agent called Dulcolax-S Tablets (Boehringer Ingelheim) was used.
Each sample was administered for 1 week and then subcutaneously injected with 4 mg / kg of loperamide (Sigma, St. Louis, Mo., USA) for 5 days in all but the normal group. Respectively.
2) Measurement of body weight, feed intake and negative water amount
The body weight was measured at the start and the last days of administration of Loperamide. Feed intake was measured daily during the experiment.
3) Number of sides, variable weight, moisture content of the sides,
The sides of each experimental animal were harvested on the fourth day after the start of the experiment. The number of the sides and the wet weight were measured.
The moisture content of the sides was calculated by drying the sides in a 70 ° C oven for 24 hours to measure the dry weight and dividing the difference between the variable weight and dry weight by the variable weight.
The number of intestinal stools was determined by counting the number of stones remaining in the large intestine after washing the organs with PBS by ligating both ends of the intestine to the rectum.
4) Statistical processing
The mean difference between the control and the experimental groups was analyzed by Student's t-test and the difference was statistically significant when the p-value was less than 0.05 Respectively.
5) Results and discussion
* Feed Intake, Negative Weight and Weight Increase *
There was no significant difference in feed intake and water intake during the experimental period, but there was no significant difference between the loperamide group (LOP) and the normal control group (NOR) And Fig. 2).
The reduction in feed intake seen with loperamide administration was not reported to affect the final weight gain ( Shimotoyodome meat al ., 2000) , the same phenomenon was also shown in this study. There was no significant difference in body weight gain between groups during the experimental period (see FIG. 3).
* Number of sides, weight *
On the 5th day after loperamide administration, the number of stools was decreased to 24.4 ± 3.78 in the Loperamide alone group (LOP) compared with 35.0 ± 2.35 in the normal control group (NOR) ± 2.59, indicating that loperamide inhibited the development of constipation.
There was no difference in the number of bowel movements when compared with the Lop group in the low concentration group (SA-1) of 24.4 ± 3.58.
However, the number of bowel movements tended to increase in the group treated with high concentration of defibrillator (SA-2), and the number of stools increased in a concentration-dependent manner compared to the constipation-inducing group (LOP) (See FIG. 4).
(SA-1, SA-2) than the control group (SC-1, SA-2) showed that the weight of the stool was also reduced in the LOP group compared to the
* Moisture content of sides *
The water content of the sides tended to decrease in the loperamide alone group compared to the normal control group (NOR), and the tendency of recovery in the positive control group (PC) tended to be recovered.
A higher water content was confirmed in the group of the fermented extract of the seeds (SC-1, SC-2) than the group treated with the water extract of the seeds (SA-1, SA-2).
* Number of intestinal sides *
On the 6th day of the experiment, the number of the stems remaining in the large intestine was confirmed by sacrificing the experimental animals.
In the loperamide alone group, the increase was 8.8 ± 0.84 compared to 4.0 ± 0.71 in the normal control group, indicating that constipation was induced by loperamide.
And 6.8 ± 0.84 in the positive control group, respectively.
It was confirmed that the number of intestinal sides was decreased by concentration in the water extract (SA-1, SA-2) and the fermented extract-treated group (SC-1, SC-2) The number of sides of the intestines was decreased in the fermented extract-treated group, so that it was confirmed that the induction of constipation was reduced (Figs. 7A and 7B).
Loperamide is a drug used as a branching agent but inhibits intestinal motility and prolongs the time taken for defecation ( Schilleret al ., 1984 ) are used to induce constipation in experimental animals. In this study, the administration of loperamide resulted in the number of stools, weight loss, and intestinal residual stool count. The symptom of constipation was mitigated by the fermentation extract of luciferase.
In addition , there was a possibility that loperamide could inhibit intestinal motility and increase intestinal water uptake or inhibit secretion ( Read, 1983; Theodoru et al., 1991 ) . In this experiment, , And the effect of the fermented extract of the luciferase on the moisture content of the stomach.
Claims (21)
(B) feeding the culture solution of lactic acid bacteria to the aqueous solution of the recipient;
A step of sterilizing the aqueous solution of the defibrillator supplied with the lactic acid bacteria growth medium;
접 Inoculating one kind of lactic acid bacteria selected from the group consisting of Lactobacillus acidophilus , Lactobacillus paracasei and Enterococcus faecium into the sterilized aqueous solution of the lysate,
Fermenting an aqueous solution of a lysate of the lactic acid bacteria inoculated;
Centrifuging the fermented fermentation broth to obtain a supernatant;
Which comprises administering to a recipient an effective amount of a compound of formula (I).
The aqueous solution of the defibrillator in step (a)
The method for preventing and / or improving constipation using a defibrillator according to claim 1, wherein the defibrillator powder is supplied to a concentration of 2 to 8 wt% [W / V] of a defibrillator powder in distilled water and 30 to 70 소 of a defoamer.
The defoamer of step (a)
wherein the preservative is selected from the group consisting of decanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, mineral oil, oxystearine, dimethyl polysiloxane, silicon dioxide, sorbitan monostea rate and silicon resin. ≪ / RTI >
The lactic acid bacteria growth medium of step (b)
Wherein the composition is a mixture of Proteose Peptone, Beef Extract, Yeast Extract, Dextrose, Polysorbate 80, Ammonium Citrate, Sodium Acetate, Magnesium Sulfate, Manganese Sulfate and Dipotassium Phosphate.
The sterilization treatment in the step (a)
Characterized in that the composition is sterilized by high pressure steam at 115 - 125 캜 for 10 - 20 minutes.
In the above step,
The method for preventing and / or improving constipation according to claim 1, wherein the sterilizing agent is inoculated in an amount of 0.9 to 1.2 L of the aqueous solution of the defibrillator and 30 to 50 mL of the lactic acid bacterium.
The fermentation in the step (a)
Wherein the composition is fermented while stirring at 120 - 180 RPM while supplying oxygen at 35 - 40 < 0 > C.
The supernatant of step (b)
Wherein the supernatant is centrifuged at 5,000 to 10,000 RPM for 10 to 20 minutes to obtain a supernatant.
(B) preparing an aqueous solution of a defibrillator by adding a defibrillator extract and defoamer to distilled water;
(B) supplying a lactic acid bacterium growth medium to the aqueous solution of the recipient;
A step of sterilizing the aqueous solution of the defibrillator supplied with the lactic acid bacteria growth medium;
A step of inoculating one kind of lactic acid bacteria selected from the group consisting of Lactobacillus acidophilus , Lactobacillus paracasei and Enterococcus faecium into the aqueous solution of the sterilizer;
(C) fermenting an aqueous solution of the recipient inoculated with the lactic acid bacteria;
Centrifuging the fermented fermentation broth to obtain a supernatant;
Which comprises administering to a recipient an effective amount of a compound of formula (I).
The Cassiae Extract of step (a)
1% by weight of selected dried-off lycopers or lucifer powder: 9 to 11% by weight of distilled water to prepare a mixture;
Heating the mixture to 100 - 120 캜 for 2 - 4 hours;
Filtering the suspended matter or precipitate after cooling the heated Cassiae extract;
Concentrating the filtered killer extract at reduced pressure;
And then lyophilizing the concentrated concentrate under reduced pressure. The method for preventing and / or improving constipation using a defibrillator according to claim 1,
In the step (b) above,
Wherein the defatted powder is supplied to the distilled water in a concentration of 2 - 8 wt% [W / V] of the defatted powder, and 30 - 70 소 of defoamer is supplied.
The anti-
wherein the preservative is selected from the group consisting of decanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, mineral oil, oxystearine, dimethyl polysiloxane, silicon dioxide, sorbitan monostea rate and silicon resin. ≪ / RTI >
The lactic acid bacterium growth medium in step (b)
Wherein the composition is a mixture of Proteose Peptone, Beef Extract, Yeast Extract, Dextrose, Polysorbate 80, Ammonium Citrate, Sodium Acetate, Magnesium Sulfate, Manganese Sulfate and Dipotassium Phosphate.
The sterilization treatment in the step (a)
Characterized in that the composition is sterilized by high pressure steam at 115 - 125 캜 for 10 - 20 minutes.
In the above step,
The method for preventing and / or improving constipation according to claim 1, wherein the sterilizing agent is inoculated in an amount of 0.9 to 1.2 L of the aqueous solution of the defibrillator and 30 to 50 mL of the lactic acid bacterium.
The fermentation in the step (a)
Wherein the composition is fermented while stirring at 120 - 180 RPM while supplying oxygen at 35 - 40 < 0 > C.
The supernatant of step (b)
Wherein the supernatant is centrifuged at 5,000 to 10,000 RPM for 10 to 20 minutes to obtain a supernatant.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140046804A KR101628962B1 (en) | 2014-04-18 | 2014-04-18 | manufacturing method of preventing and ameliorating constipation thereof |
| PCT/KR2014/007609 WO2015160043A1 (en) | 2014-04-18 | 2014-08-18 | Constipation prevention and alleviation agent using cassia tora l. and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140046804A KR101628962B1 (en) | 2014-04-18 | 2014-04-18 | manufacturing method of preventing and ameliorating constipation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150121362A KR20150121362A (en) | 2015-10-29 |
| KR101628962B1 true KR101628962B1 (en) | 2016-06-10 |
Family
ID=54324226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140046804A KR101628962B1 (en) | 2014-04-18 | 2014-04-18 | manufacturing method of preventing and ameliorating constipation thereof |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101628962B1 (en) |
| WO (1) | WO2015160043A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101689192B1 (en) * | 2014-11-04 | 2016-12-26 | 해남자연농업영농조합법인 | Lactobacillus kefiri strain for enhancing activity of improving or preventing constipation by fermenting Cassia |
| GB201601558D0 (en) * | 2016-01-28 | 2016-03-16 | Verdant Bioproducts Ltd | Method for producing 3-hydroxypropionamide |
| KR102021774B1 (en) * | 2019-05-03 | 2019-09-17 | 이혜현 | Composition for bowel movement promotion or diet and manufacturing method thereof |
| CN110973547A (en) * | 2019-12-20 | 2020-04-10 | 湖南橘色科技有限责任公司 | Rhizoma polygonati enzyme jelly and preparation method thereof |
| CN112544920A (en) * | 2020-12-03 | 2021-03-26 | 山东腾贵医药有限公司 | Composition for improving constipation and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100512322B1 (en) | 2004-07-09 | 2005-09-02 | 김양문 | Double-fermented bio-zyme liquid having an improvement effect of constipation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100344325B1 (en) | 1998-05-02 | 2002-11-18 | 주식회사 태평양 | Tea product improving constipation and production thereof |
| KR100427562B1 (en) * | 2002-01-17 | 2004-04-28 | 주식회사 태평양 | Powder of Cassia Tora L. and tea containing the same for treating constipation |
| KR100584153B1 (en) | 2002-07-25 | 2006-05-29 | 서울향료(주) | Manufacture method, Various uses and Extracts for The Development of Anticonspitation Functional food materials from Oriental Herbal Medicines |
| KR20090123458A (en) * | 2008-05-28 | 2009-12-02 | 주식회사 엘씨에스바이오텍 | A method for fermentation of natural plants or herbal medicines, a fermented product prepared therefrom and a cosmetic composition, a food composition and a pharmaceutical composition comprising the same |
-
2014
- 2014-04-18 KR KR1020140046804A patent/KR101628962B1/en active IP Right Grant
- 2014-08-18 WO PCT/KR2014/007609 patent/WO2015160043A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100512322B1 (en) | 2004-07-09 | 2005-09-02 | 김양문 | Double-fermented bio-zyme liquid having an improvement effect of constipation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150121362A (en) | 2015-10-29 |
| WO2015160043A1 (en) | 2015-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101628962B1 (en) | manufacturing method of preventing and ameliorating constipation thereof | |
| JP7201837B2 (en) | Composition for prevention, improvement or treatment of obesity or fatty liver disease containing Leuconostoc citreum WIKIM0104 | |
| JP5569710B2 (en) | Obesity preventive or ameliorating agent | |
| JP6684966B2 (en) | Novel Lactobacillus sakei and composition containing the same | |
| JP2017509636A (en) | Composition comprising post-fermented tea extract | |
| CN101926428B (en) | Probiotic gingko pollen freeze-dried powder and preparation method thereof | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| WO2020175939A1 (en) | Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising weissella hellenica wikim0103 | |
| JP2021527414A (en) | Composition for improving intestinal function containing a strain of Leuconostocaceae | |
| CN115089619A (en) | Application of lactobacillus plantarum ZDY2013 in preparation with function of relieving non-alcoholic fatty liver disease | |
| CN106924477B (en) | Composite traditional Chinese medicine fermentation preparation produced by mixed bacteria fermentation and preparation method thereof | |
| KR102162143B1 (en) | Composition for preventing, improving or treating the degenerative brain diseases comprising Pediococcus inopinatus WIKIM27 | |
| KR101133208B1 (en) | Method Manufacturing of Functional Fermented Soybean materials for improving the intestine function and constipation Using Plant?Originated Lactic Acid Bacteria and Bacillus | |
| CN108938789A (en) | A kind of more bacterium combination formulations of the adjusting intestinal microecology containing xylo-oligosaccharide | |
| AU2019416609B2 (en) | Kimchi for preventing or treating helicobacter pylori-associated diseases | |
| CN112870253A (en) | Flos puerariae extract for improving intestinal micro-ecological imbalance | |
| CN111248384A (en) | Composite probiotic enzyme beverage and preparation method thereof | |
| JP6894242B2 (en) | Non-alcoholic liver disease inhibitor | |
| CN105707898A (en) | Toxin removing and bowel relaxing probiotic composition and preparation method and application thereof | |
| CN104940375A (en) | Production method for lactic acid bacteria fermented poplar flower oral liquid | |
| KR101808306B1 (en) | Lactobacillus casei strain for enhancing activity of improving or preventing constipation by fermenting Cassia | |
| JP5562986B2 (en) | Preventive or ameliorating agent for lifestyle-related diseases | |
| CN103461612A (en) | Food stomach-nourishing tea electuary protecting stomach lining | |
| CN108379440A (en) | Multifunctional feed additive | |
| CN113046274B (en) | Lactobacillus reuteri for relieving gastrointestinal injury caused by capsaicin and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190409 Year of fee payment: 4 |